Share Your News Now

If you would like to share news or information with our readers, please send the unique stories, business news organization events, and school news to us includinig your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact
John Robbins 281-965-6390
Jun Gai 281-498-4310

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com

Pandemic Cancels Texas African Business Summit

Inside C2

Sunday, December 13, 2020

UK to refine allergy warning on Pfizer vaccine sparked by two adverse reactions

George Dyer, 90, receives the first Pfizer/BioNTech COVID-19 vaccine, administered by General manager of Covid Recovery Becky Board, at Croydon's University Hospital, on the first day of the largest immunisation programme

LONDON (Reuters) - Britain's medicine regulator warned people with significant allergies not to get Pfizer-BioNTech's COVID-19 vaccine after two people suffered adverse reactions, but was set to give more detailed guidance on Wednesday based on reviews of those cases.
George Dyer, 90, receives the first Pfizer/BioNTech COVID-19 vaccine, administered by General manager of Covid Recovery Becky Board, at Croydon's University Hospital, on the first day of the largest immunisation programme in the British history, in London, Britain December 8, 2020. Dan Charity/Pool via REUTERS
Starting with the elderly and frontline workers, Britain began mass vaccinating its population on Tuesday, part of a global drive that poses one of the biggest logistical challenges in peacetime history.

National Health Service medical director Stephen Powis said the advice had been changed as a precaution after two NHS workers reported anaphylactoid reactions from the vaccine.

"Two people with a history of significant allergic reactions responded adversely yesterday," Powis said. "Both are recovering well."

The Medicines and Healthcare Products Regulatory Agency (MHRA) initially advised anyone with "a history of a significant allergic reaction to a vaccine, medicine or food" to avoid taking the vaccine.

However, by the end of Wednesday that guidance was set to be refined after discussions with experts on the nature of the reactions.
"We're tweaking advice to make it very clear that if you've got a food allergy, you're not more at risk," Imperial College London's Paul Turner, an expert in allergy and immunology who has been advising the MHRA on their revised guidance, told Reuters.

Pfizer and BioNTech said they were supporting the MHRA's investigation.

Last week Britain's MHRA became the first in the world to approve the vaccine, developed by Germany's BioNTech and Pfizer, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to assess the data.

A top U.S. official said on Wednesday that Americans with known severe allergic reactions may not be candidates for Pfizer's COVID-19 vaccine until more was understood about what had happened.

Canada's health ministry said it would look at the reported adverse reactions in Britain, but said adverse events were to be expected and would not necessarily change the risk/benefit of the shot, after the country approved the vaccine.

RELATED COVERAGE

UK medicine regulator examining Pfizer vaccine reactions as matter of priority
ALLERGIC REACTION
MHRA Chief Executive June Raine told lawmakers such allergic reactions had not been a feature of the Pfizer's clinical trials.

Pfizer has said people with a history of severe adverse allergic reactions to vaccines or the candidate's ingredients were excluded from their late stage trials, which is reflected in the MHRA's emergency approval protocol.

However, the allergic reactions may have been caused by a component of Pfizer's vaccine called polyethylene glycol, or PEG, which helps stabilise the shot and is not in other types of vaccines.

Imperial College London's Turner said: "As we've had more information through, the initial concern that maybe it affects everyone with allergies is not true.

"The ingredients like PEG which we think might be responsible for the reactions are not related to things which can cause food allergy. Likewise, people with a known allergy to just one medicine should not be at risk," Turner told Reuters.

The EMA said in an email that all quality, safety and efficacy data would be taken into account in assessing the vaccine, including data generated outside the EU.

In the United States, the FDA released documents on Tuesday in preparation for an advisory committee meeting on Thursday, saying the Pfizer vaccine's efficacy and safety data met its expectations for authorization.
The briefing documents said 0.63% of people in the vaccine group and 0.51% in the placebo group reported possible allergic reactions in trials, which Peter Openshaw, professor of experimental medicine at Imperial College London, said was a very small number.

"The fact that we know so soon about these two allergic reactions and that the regulator has acted on this to issue precautionary advice shows that this monitoring system is working well," he said.

However, Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic in Rochester, Minnesota, said that the MHRA and NHS had overreacted initially.

"I would not have broadened to the degree they did," he said.

"It's reasonable to let the world know about this, and to be aware of it in terms of people who have had reactions like this to vaccines. I think to say medicines, foods or any other allergies is past the boundary of science."

WEA LEE'S GLOBAL NOTES

12/12/2020

CORONAVIRUS DIARY

Wealee@scdaily.com

America Is In Hell

The United States reported 108,044 COVID–19 hospitalizations on Friday, setting the highest record since the pandemic began. This is the tenth consecutive day that the U.S. has remained above 100,000 hospitalizations.

Today in Washington, D.C. President Trump signed a one–week stopgap funding bill to avert a government shutdown at midnight.

The Supreme Court today rejected a bid from Texas' s attorney general supported by Trump to block the ballots of millions of voters in the battleground states that went in favor of president–elect Joe Biden.

On Wednesday Biden' s son Hunter was under tax investigation, but federal prosecutors in Delaware now are looking into his dealings with a Chinese businessman.

White House Chief of Staff Mark Meadows today told FDA chief Dr. Stephen M. Hahn that a vaccine must be authorized by Friday or he needs to resign.

We are very sad to see what is going on around the nation. Many people are losing their lives to the COVID–19 virus and we still don' t see any measures being put into place to slow down the pandemic. Our only hope now is the vaccine.

Southern News Group Chairman / CEO
Chairman of International Trade & Culture Center
Chairman of International District Houston Texas

Stay Home! **BUSINESS** *Wear Mask!*

Reduces Death Rates Among Patients With Severe Cases

Common Steroid Improves COVID-19 Survival - Study



Compiled And Edited By John T. Robbins, Southern Daily Editor

A cheap, readily available steroid drug reduced deaths by a third in patients hospitalized with Covid-19 in a large study, the first time a therapy has been shown to possibly improve the odds of survival with the condition in the sickest patients.

Full data from the study have not been published or subjected to scientific scrutiny. But outside experts on Tuesday immediately embraced the top-line results. The drug, dexamethasone, is widely available and is used to treat conditions including rheumatoid arthritis, asthma, and some cancers.

In a statement, Patrick Vallance, the U.K. government's chief scientific adviser, called the result "tremendous news" and "a ground-breaking development in our fight against the disease." Scott Gottlieb, a former commissioner of the U.S. Food and Drug Administration, called it "a very positive finding" in an interview on CNBC. "I think it needs to be validated, but it certainly suggests that this could be beneficial in this setting."

Related

Atul Gawande, the surgeon, writer and public health researcher, urged caution, tweeting, "after all the retractions and walk backs, it is unacceptable to tout study results by press release without releasing the paper."

The study randomly assigned 2,104 patients to receive six milligrams of dexamethasone once a day, by mouth or intravenous injection. These were compared to 4,321 patients assigned to receive usual care alone.

In patients who needed to be on a ventilator, dexamethasone reduced the death rate by 35%, meaning that doctors would prevent one death by treating eight ventilated patients. In those who needed oxygen but were not ventilated, the death rate was reduced 20%, meaning doctors would need to treat 25 patients to save one life. Both results were statistically significant.

There was no benefit in patients who didn't require any oxygen. The researchers running the study, called RECOVERY, decided to stop enrolling patients on dexamethasone on June 8 because they believed they had enough data to get a clear result.

"Dexamethasone is the first drug to be shown to improve survival in COVID-19," Peter Horby, one of the lead investigators of the study and a professor in the Nuffield Department of Medicine at the University of Oxford, said in a statement. He added that the drug should now become the standard treatment for patients with Covid-19 who need oxygen. "Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.'"

APSTOCK

A different arm of the same study showed on June 5 that hydroxychloroquine, widely touted as a potential Covid treatment, had no benefit in hospitalized patients. Yesterday, based in part on those results, the Food and Drug Administration revoked an Emergency Use Authorization for using hydroxychloroquine in those patients.

From the start of the pandemic in March, researchers have focused on two different stages of Covid-19, which will likely require very different interventions. Some drugs are designed to directly combat the novel coronavirus, SARS-CoV-2, that causes the disease. The first medicine shown to have a benefit, remdesivir from the biotech firm Gilead Sciences, falls into this category, even though, because it must be given intravenously, it has been tested in hospitalized patients. Remdesivir shortens the course of infection, but has not been shown to save lives.

After patients have become profoundly sick, the problem starts to become not only the virus but their own immune system, which attacks the lungs, a condition called acute respiratory distress syndrome, or ARDS. For these patients, doctors have believed, they would need to dampen patients' immune response even as they fought the virus.

Initially, excitement in this area fell on new and expensive drugs, such as Actemra, a rheumatoid arthritis drug from Roche that is used to treat a similar condition caused by some cancer immunotherapies. But a study in patients who needed oxygen showed no benefit from a similar drug, although another arm in sicker patients is continuing. The National Institutes of Health is conducting a study of an Eli Lilly pill targeting rheumatoid arthritis, an extension of the study that showed remdesivir has a benefit.

Dexamethasone, which reached the market 59 years ago, seemed an unlikely candidate to help these patients; it was seen as too crude a way of tamping down the immune system. In guidelines for physicians treating the disease, the NIH doesn't even mention the therapy. Studies that are testing other medicines may now need to incorporate the use of the drug, which could complicate analyzing the results. A spokesperson for Regeneron, which is testing Covid-19 drugs focused on both attacking the virus and dampening the immune system, said the company's studies are written so that when a new medicine becomes the standard of care, it becomes available to patients in the trial.

Some studies have shown a benefit for using dexamethasone in acute respiratory distress syndrome not related to Covid-19, although the benefit was smaller than in RECOVERY.

The result, should it hold up to further scrutiny, shows the benefit of the strategy of Horby and Martin Landray, the Oxford researchers who designed the study, leveraging the U.K. health system to start a study of multiple inexpensive potential Covid-19 therapies — including hydroxychloroquine, dexamethasone, and also some older HIV medicines. Several months into the Covid-19 pandemic, two of the most important results come from this single study. Neither of those results, however, have been scrutinized or published. (Courtesy stastnews.com)

Southern DAILY Make Today Different

Editor's Choice

A member of Lebanese army walks past the rubble at the site of a blast in Beirut's port area, Lebanon, August 7, 2020. REUTERS/Mohamed Azakir

Best Supporting Actor winner Brad Pitt waits for his Oscar statue to be engraved at the Governors Ball following the 92nd Academy Awards in Los Angeles, California, February 9, 2020. REUTERS/Eric Gaillard

People dance at a park almost a year after the global outbreak of the coronavirus in Wuhan, Hubei province, China. REUTERS/Aly Song

A migrant carries her belongings following a fire at the Moria camp for refugees and migrants on the island of Lesbos, Greece, September 9, 2020. REUTERS/Elias Marcou

Azeri service members guard the area, which came under the control of Azerbaijan's troops following a military conflict over Nagorno-Karabakh against ethnic Armenian forces and a further signing of a ceasefire deal, on the border with Iran in Jabrayil District. REUTERS/

A boy gestures as a man in a Haitian National Police uniform aims a gun during a shooting in Champ de Mars, Port-au-Prince, Haiti, February 23, 2020. REUTERS/Andres Martinez Casares



The headquarters of the Kurdistan Democratic Party (PDK) is seen after it was burnt during anti-government protests on the outskirts of Sulaimaniyah, Iraq. REUTERS/Ako Rasheed

Neonatal nurse Kirsty Hartley carries newborn Theo Anderson, who was born prematurely, to his mother Kirsty Anderson, in the Neonatal Intensive Care Unit at the Lancashire Women and Newborn Centre at Burnley General Hospital, during the coronavirus outbreak, in Burnley, East Lancashire, Britain, May 15, 2020. REU-

Southern DAILY Make Today Different

COMMUNITY

More Than 300 Texas Hospitals To Receive 'Bamlanivimab,' Experimental Antibody Treatment For COVID-19

Compiled And Edited By John T. Robbins, Southern Daily Editor

The U.S. Food and Drug Administration authorized bamlanivimab for Emergency Use. Eli Lilly and Company created the drug. It is authorized for for treating mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization, according to Lilly.

Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. Health care workers give it via intravenous infusion.

Clinical trials showed it could prevent a patient from going to the hospital. That indication could help our health care workers who have been battling the virus for eight months.

"I'm very proud of our people and all the healthcare workers in Houston. They've really stepped up to the challenge and continued to provide really great care, but it is wearing, and it's something we worry about as the pandemic continues to be present," said Dr. David Callendar, President and CEO of Memorial Hermann.

Governor Greg Abbott's office said hospitals in Texas should receive it as soon as next week.

DSHS will allocate this first distribution of bamlanivimab based on three criteria: new confirmed cases of COVID-19 in the community, new lab-confirmed COVID-19 admissions to hospitals, and total lab-confirmed COVID-19 patients in hospitals.

"This initial allotment of bamlanivimab will help health care professionals effectively treat cases of COVID-19 within their communities and aid in reducing hospitalizations," Gov. Abbott said. "I thank the U.S. Department of Health and Human Services for providing Texas with this crucial antibody therapy that will help keep Texans safe and mitigate the spread of COVID-19."

Texas is receiving the second-highest number of shipments of the drug, behind Illinois, according to DSHS.

Hospitals in the Houston and Galveston/Beaumont trauma service areas will receive more than 700 doses. Each patient receives one dose, according to DSHS.

A spokesperson said they expect weekly shipments from the federal government.

U.S. FOOD & DRUG ADMINISTRATION

Chris Costa
@ChrisCostaTV
Nov 13
@TexasDSHS
tells me they've allocated it to 300+ hospitals across TX. For the first round, more than 700 doses (1 per person) will be going to #Houston and #Galveston / Beaumont trauma service areas. Expecting add'l allocations from fed govt every week
@KHOU
#khou11 #COVID19

==========

Gov. Greg Abbott
@GovAbbott
@TexasDSHS
is allocating an initial shipment of bamlanivimab, the
@LillyPad
monoclonal antibody therapy, to be distributed as early as next week to acute care hospitals across the state to help effectively treat #COVID19 & aid in reducing hospitalizations.

Office of the Texas Governor | Greg Abbott

These weekly shipments of doses have been provided to the state at no cost through the U.S. Department of Health and Human Services.

"It's going to be a big benefit to us," said Chris Van Deusen, Director of Media Relations for Texas DSHS. "Every time we see a new medication, something that looks promising, it's a step in the right direction, and we're one step closer to finally getting through this issue."

Lilly anticipates manufacturing up to 1 million doses of bamlanivimab 700 mg by the end of 2020, for use around the world through early next year.

• Bamlanivimab is **NOT** authorized for use in patients:

o who are hospitalized due to COVID-19, OR

o who require oxygen therapy due to COVID-19, OR

o who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related co-morbidity.

Doctors are urging people to be extra diligent with masking and social distancing, even around close friends and family, to prevent a second surge. Dr. Callendar said roughly 50 percent of people who test positive for COVID-19 show no signs of being sick.

"I think we still have time to control this one – keep it from becoming what we saw in the middle of the summer," Dr. Callendar said.

His message comes as Texas' rates of COVID-19 soar back to more than 10,000 cases a day for three straight days. The last time Texas saw those levels was in mid-July, the worst of the pandemic.

"It's still going to take everybody taking those everyday steps to really put a dent in that big increase in cases we've seen recently," Van Deusen said.

Related

Arthritis drug 'cuts elderly Covid-19 deaths by two-thirds', say researchers - raising hopes that it will save the most vulnerable

KEY POINTS

Daily drug reduces deaths by 71 per cent in those with moderate or severe illness

Drug baricitinib, marketed as Olumiant, has only been available for three years

Medics hope the arthritis drug could help save most vulnerable to coronavirus

An arthritis drug has been found to cut deaths in patients admitted to hospital with COVID-19 by a remarkable two-thirds – giving medics a powerful new weapon in their armoury against the disease.

The daily pill, first earmarked as a potential Covid game-changer by a British firm, reduces deaths by 71 per cent in those with moderate or severe illness, researchers say.

Importantly, it works in the elderly, raising hopes that it will save the most vulnerable.

Called baricitinib, and marketed under the brand name Olumiant, it is a relatively new drug for rheumatoid arthritis that has been available for only three years.

An arthritis drug has been found to cut deaths in patients admitted to hospital with Covid-19 by a remarkable two-thirds. Picture: Stock

But in February it was identified as a strong candidate to help treat what was then the new threat of Covid-19. The drug was picked out by London-based BenevolentAI, which examined thousands of existing medicines for signs they might combat Covid.

Its artificial intelligence program predicted baricitinib would 'reduce the ability of the virus to infect lung cells'.

Now the idea has been validated with pan-European researchers, led by Sweden's Karolinska Institute, reporting baricitinib slashes death rates in those admitted to hospital with the disease by two-thirds. (Courtesy www.dailymail.co.uk/)

SC 婚姻觀 Daily News

关于婚姻
你需要知道点新鲜的

婚姻是一门学问，仅有激情是不够的，貌似稳定的关系仍会面对很多大大小小的矛盾冲突，甚至可能最终分道扬镳。

要想与另一半建立起持久、稳固的恋情，你需要掌握一定的技巧，尤其要注意，不要让以下的这些因素毁了你们好不容易建立起的关系。

婚姻法不保护感情，法律没有规定一个人必须爱另一个人一辈子。

无论是新婚夫妇还是相濡以沫的老夫老妻，婚姻这门课是我们一生要学习的，因为婚姻影响着一个人及一个家。

婚姻中大多数痛苦，都来源于攀比。

常说"你为什么不能像人家老公、人家老婆一样呢？"

挂在口边，抱怨丈夫赚得少，抱怨妻子脾气不好，却常常忽略了自己妻子或者丈夫的优点。

一个人的心不是靠抢夺和抓住就能留下，而是一颗心走向另一颗心。

好的夫妻关系，没有期待，各自强大，这样才能创造精彩。

婚姻是什么？没有步入婚姻的人，很难真正理解这种没有血亲却又千丝万缕的联系。

它神圣，而庄重。

你是我交过命的人，请一定要好好珍惜，这一世的夫妻情分。

因为每一段婚姻走到最后，都是生命对生命的托付。

婚姻是为了更深的东西：

为了亲密，为了一种相互归属，为了要去做一个人无法单独做的事，为了要去做两个人可以一起做的事，为了要去做一种需要两个人在一起、深深地在一起才能够做的事。

生命的本质就是爱，而婚姻是给爱，找一个家。

心若没有栖息的地方，到哪都是流浪。

我们经常不被允许做真实的自己，被许多约定俗成的信念所制约，当一个生命想要跳出制约。

活出真实的自己时，往往会被抗拒和拒绝。

如果一开始的感受是被束缚的，我相信许多人不会走入婚姻。

我们终其一生，需要的是一个愿意注视着我们的人，一个愿意敞开心扉被我们注视的人。

世界那么大，诱惑那么多，可我的目光只追随着你，与你对视。

任皱纹堆砌在脸上，任身体被时间侵蚀，在彼此欣赏和期待的目光中，任性地做着你的爱人。

这样的婚姻，难道不是我们终其一生追求的吗？

而婚姻中的那个人，是我们想要如实表达真实自己的那个人，现实却往往不随人愿。

当走进婚姻的那一刻，双方不再真实，不再袒露自己的心扉。

许多人的婚姻就算两个人在一起，也是很冷清的。

厨房里的萧条，客厅里的沉默，还有卧室里的相看两厌。

多少人，都是在婚姻失败后，才意识到，自己当年是毫无准备就走进了婚姻。

没有任何一段婚姻是可以躺在过去偷懒的，这就像开一家店，再好的地段，也是需要好好经营的。

萧伯纳说：反正结婚，不结婚你们都会后悔的。

你在山洞里清净打坐十年，带给你的心灵成长，都不及你和自己的伴侣相处一个月。

婚姻除了生养孩子，真的是人世间最伟大的一场心灵成长游戏，你可以不去互动，你同时也失去了最快速，最深刻成长的机会。

你期待婚姻它好的一面，也得去接纳它带给你的成长之前的痛苦。

结婚其实是两个人的结合与两个家庭的相遇，你们的婚姻中不可避免的会出现婆媳关系、姑嫂关系等，这些你们会怎么面对？

婚姻再往前走一步，就会遇见孩子，遇见你们此时最珍视的那个人。

亲子关系也是对夫妻关系的考验，这些你们会怎么面对？

幸福的婚姻，是两个人彼此努力靠近的结果；

而不幸的婚姻，只需要一个人，用放大镜挑着另一个人的缺点，就已经足够了。

在彼此热爱的人眼中，变老变丑，都是浪漫的事情；

在不知满足、不会感恩的人眼中，爱人在马桶上的样子，都颠覆了女神的形象，可以成为攻击的理由。

在感情中，有太多人看似"沧桑"，心理上却是伴侣的"孩子"，他们自私、懦弱、贪婪、喜欢逃避……

而更可悲的是，他们可能意识不到自己的身上存在问题，而习惯去指责和抱怨对方。

所以，在婚姻中，每一点一滴的小细节，都能体现出我们对婚姻的责任感和对伴侣的爱，而积攒失望，只会感情破裂。

婚姻让人找到了共同生活的伴侣，人们倾向于在婚姻中寻找安全感和稳定性，随着时间的推移，只是为了满足彼此需要而存在的婚姻会慢慢失去激情。

如果夫妻可以保持自己的独立性，让对方看到自己在熟悉的领域活跃着，就可以始终保持一种新鲜的视角去看待对方。

建议：如果你想继续保留激情的火花，那么就给你的伴侣留出空间，让伴侣去做自己擅长的事情。

当伴侣展现出自信时，要趁此机会好好欣赏对方。

当然，许多人在婚姻中会面临一个情况：婚外情

心理学家试图让出轨者列举出为什么是那个人？

究竟是什么提供给了这些处于稳定婚姻中的人这么大的诱惑，不顾一切的冒险呢？

虽然出轨的理由不尽相同，这其中竟暗含着一个相似的主题。

那就是：外遇是发现自我的一种方式，是对新的（或丢失的）人格身份的寻找。

为什么处于稳定感情状态中的人也有可能出轨。

有时候我们躲避着爱人的目光，不是真的在躲避他们，而是在躲避这个陈旧的自己。

许多在外遇中收获最多的并不是外遇对象，而是一个重新焕发着光芒的自己，一个新的自己。

或者是在婚姻当中不被认可的那个自己。

很多成年女性的心里，都住着一个渴望被爱的小女孩。

"她"希望被人关注，被人重视，被人疼爱。

因为只有被爱时，"她"才能强烈地感受到自我存在的价值。

男人为了证明自己是个完整的男人，可能会作出任何事情。

这种人仍在挣扎着向别人证明自己是独立的，自己是个男人

出轨是因为觉得自己毫无价值，觉得世界上并没有人会真的爱他们。

低自尊的人总是对生活缺乏一种安全感，通过拥有关系外伴侣的形式来证明自己是具有性吸引力的，而且，他们需要持续不断地这种确认，因此可能会拥有不止一个出轨对象，或者持续处于出轨的状态中。

婚姻既是爱情的结合，也是在此基础上继而产生亲情、友情的一种特别情感。

如果光有爱情没有亲情，还能继续维持。

如果婚姻里没有爱情，只有亲情或友情，那婚姻将如一潭死水，无法得到良性循环。

相识，相知，相爱，相守，相濡以沫，相伴一生。

婚姻就像通关游戏，每一关都有挑战，也都是成长。

被击穿的「蛋壳公寓」中介互联网的倒台范本

随着蛋壳公寓的暴雷，再看它官网写的东西，很多内容现在看起来就格外讽刺了。

比如它的口号——用科技让生活变得简单和快乐。

租房中介自古有之，可行业口碑一向不太好，即便如此，一手收租金、一手加价的商业模式，大不了买卖双方被坑点房租，其实模式蛮简单的。

然而现在却被搞成了不花点功夫根本看不懂的金融业，还闹出人命，难免有些令人唏嘘了。

简单而言，蛋壳公寓的业务运转模式，收的不是租户租金，是利用租户的信用建立的银行长期贷款，而蛋壳拿到租金之后，并不会直接付给房东，而是转手再去用来收房源。

这其实是一个空手套白狼的故事：信用是租户的，房子是房东的，资金是银行的。

官网介绍里又特别强调，蛋壳是“大学毕业生成长计划”的独家租房战略合作伙伴。

可这届打工人又到底得罪谁了，毕业了赶上疫情，工作不好找，租个房子还赔钱，更可能背上不良信用记录。

不过，蛋壳公寓暴雷，却是一切「中介互联网」平台口碑骤降的缩影。

「中介互联网」一词，是我临时起意，用于所有「蛋壳公寓们」的统称。

是因为多数互联网平台，表面看起来是高科技公司，但实际做的都是最古老的中介生意。

拿搜索引擎来说，本质上可被看作「资讯的中介」，左手汇聚各个网站的内容，中间经过算法，右手匹配搜索关键词分发给用户。

而电商平台，是「商品广告的中介」，左手是无数大中小商家，中间还是算法，右手推荐给目标用户。

我们当然不能否认中介互联网平台带给人们便利性，不然试想一下：如果现在要查点信息，都变成过去图书馆翻报纸的情况，世界会变成怎样。

我们承认中介互联网的价值，但是人们也越来越认识到，便利性的背后是有巨大社会代价的。

代价之一，中介算法的公正性。

常用搜索引擎的人知道，对用户来说，我们看什么，买什么，玩什么，用什么词搜索不是关键，中间的算法才是关键，毕竟头几条都是广告。

你以为你在搜索，其实是平台在帮你做搜索。

而对内容上游网站而言，搜索引擎把你Kill了，就相当于一场搜索引擎展开的“网络谋杀”。

谁来决定中间算法的公正性，是世界难题，全球都无解。

可能有人会说这还不简单，加强政府监管就是了，可难道大家这么快就把某政府主导的棱镜门忘了？

代价之二，在于中介的“税收”问题。

中介互联网的商业模式，可以总结为一点——控制市场，获得垄断，对市场“收税”。

这就要从中介互联网的发展历程说起，可以分成早期和晚期的各自上下半场。

早期上半场的关键词是“杨白劳”，晚期下半场的关键词是“黄世仁”。

1、杨白劳时期。

对上游来说：

在平台发展早期，平台需要商家、房东、工厂提供更丰富信息，从而吸引用户。所以中介互联网要讨好上游，大量补贴，让商家提高供应，加盟平台。早几年的打车平台，花钱补贴司机绩效就是这个道理。

对下游来说：

上半场，也是平台更需要用户。有了足够多的用户，才能吸引上游商业入驻，所以平台会通过大规模促销拉动注册和月活。用户的心理当然是“有便宜不占就是王八蛋”，所以优惠券一定是多多的发。

通过各种杨白劳行为，其中某家平台会脱颖而出，成为市场垄断者。

2、黄世仁时期。

直到垄断达成后的下半场，平台的身份就变了，由杨白劳变成收租的黄世仁。

对上游而言，如果中介平台只剩下一家，信息发布渠道被垄断。商家、房东、工厂就要求着平台要流量了，此时补贴就变成了入场费。

对用户而言，促销也就不是必需品了，因为反正用户也没有别的平台可选了。

入场费和加价费，就是平台对上下游收的“增值税”。

蛋壳公寓为什么疯狂套取资金，就是想用租户的信用做筹码，拿资金，控制房源，垄断市场。

只不过因为疫情等关系，没做好精确计算，没等控制市场具备收税能力，自己就暴雷了。

精确计算，是中介互联网平台的优势，也是它们的通病，精确会带来效率的提升，但同时意味着抗风险能力的下降。

就好比你要过一条2米宽的河，如果只准备2米1的木板，风险就比较大，一旦下雨，岸堤塌陷，河面宽了20公分，这河就过不去了。

蛋壳的问题，就是计算的太精确。万万没想到疫情之下，房屋空置率上升，拿不到足够多的租户贷款，击鼓传花的游戏就玩不下去了。

机关算尽太聪明，反误了卿卿性命。

尽管风险巨大，然而中介互联网的玩家们，还在一个个前仆后继的走上这条精算之路。

某种意义上看，中介互联网平台是裹了一层脆弱的蛋壳，都在资本的赛道上狂奔——做不成就“暴雷”，做成了就“垄断”。

也因如此，目前一切具有中介性质的互联网创新创业也变得比较无聊。

因为创意不再那么重要，主要看谁胆子大（敢加金融杠杆），看谁后台硬（资金池雄厚）。

依稀记得某个中介互联网的一句电梯广告语：“没有中间商赚差价”。这明明是彻头彻尾的反话，人类社会自古以来，就没有任何一个商业平台比中介互联网平台更会赚差价，不信大家可以看看全球市值排行榜。

比起来，这一波相对较新的新创科技互联网公司，唯一还留有光环的人就是埃隆·马斯克了。马斯克本人实际上是做金融中介起家，他是Paypal的早期参与者（创办的公司被Paypal收购了），但他发家之后，却坚决抛弃了中介，做起了实业。

做实业和做中介最大的区别在于——技术实业遵循的是摩尔定律，要不断推动产品提质降价，不然就会因为被用户诟病产品创新不足，而退出历史舞台；做中介遵循的是赢者通吃定律，只要垄断市场，就没人能管它怎么收税了。

这是由于实业产品存在固定周期性换代（产品使用年限），所以垄断市场是非常困难的（例如，iPhone的强势地位也不及十年，毕竟消费者还是会换机，手机产品还是得选型）。而中介垄断则不然，用户使用习惯心智的转移是很困难的。

中介互联网以打破传统信息不对称而出现，自身成功后，又以创造更严重的信息不对称而存在，是最大的悖论。

互联网买菜，会挤垮菜市场吗？

最近，一篇名为《互联网巨头正在夺走卖菜商贩的生计》的文章在网上广泛传播。作者在文中详细描述了自己体验“社区团购”商业模式的经历，对于互联网巨头疯狂补贴、与普通卖菜商贩争利的行为表示不满。

今年以来，受疫情影响，巨头瞄上了正处在风口上的“互联网买菜”。这一新兴模式，大大节省了消费者的时间，方便了我们的生活。不过，它也引发了网友对菜市场小商贩们的担忧。

“网上买菜”会挤垮菜市场吗？相比于线上选菜，菜市场有哪些优势？平台补贴为什么不是长久之计？菜市场的存在对一个城市意味着什么？

“羊毛” 能薅多久？

足不出户，送菜上门、下载app送现金补贴、免费送菜……数十亿甚至上百亿的现金砸向消费者，把消费者砸得晕头转向，把小菜贩砸得云里雾里。可这样的套路能持续多久呢？

可以说，“烧钱”补贴用户是互联网巨头进入新兴市场的主要手段之一，通过超大补贴力度迅速吸引大量消费者，进而在行业内实现垄断。无论是之前的网约车、共享单车和充电宝，还是如今的生鲜配送、社区电商，其实都是如此。

早年间，网络外卖平台饿了么和美团，为了培育、抢占市场，一边一单单补贴展开竞争、一边一轮轮融资烧钱。这种情况上演最激烈的时候，曾有用户一顿大餐只花了几块钱。战况之惨烈，让当年融资超过10亿美元的饿了么和融资超过20亿美元的美团都苦苦不堪支撑。2015年底，两大外卖平台格局基本已定后，筋疲力尽的双方才逐渐减小补贴。

俗话说“羊毛出在羊身上”。如今互联网巨头纷纷入局，未来网络生鲜市场格局趋于稳定之后，消费者还能薅多久的“羊毛”？互联网行业天生就具有垄断性，巨头们在培育了市场，分割了市场之后，当前消费者所享受的这些补贴可能将不复存在。

所以说，“烧钱”培养、抢占市场，只是一时之计，而非长久之策。对消费者而言，在没有“羊毛”可薅后，用什么方式和渠道买菜，也会逐渐恢复多样化。

菜市场的优势，互联网做得到吗？

出门去菜市场现场挑，还是在互联网平台上动动手指选？今年受疫情影响，似乎越来越多的人在考虑后者。难道，未来菜市场的生存空间将会被不可逆转地挤占吗？

事情没有那么简单。菜市场的独特魅力，互联网是“复刻”不来的。

从体验上来讲，与在小商贩处买菜相比，“云买菜”具有极大的不确定性，无法带来“可触可感”的体验。

对比一下感受会更直观。比如在互联网公司早已攻城略地的出行服务领域，无论传统打的还是互联网叫车，用户关心更多的还是能否“到达目的地”，而对路上的行程不那么在意。

可去菜市场买菜，图的就是能亲自调动各种感官来比对、最终挑选出新鲜完整食材的这一过程，图的是一份确定和安心。但是，平台下单的消费者无法直观感受食材的品质，这无疑是一种缺憾。

另外，两者在交易逻辑上的差异，也彰显了菜市场的不可替代性。

我们可能会遇上这样的场景，在网上买了一个生鲜产品，到手后发现有问题，对方不太会愿意上门换货，因为来拿一趟的成本比产品本身的价格高得多。最后商家往往会退款。但我们要的是产品，拿着退款有什么用呢？再说，中间折损的时间成本又怎么衡量？

另一方面，作为一种新兴技术，互联网的确起到了信息中介的作用，把相隔万里的需求和供给瞬间撮合在了一起。但同时，这也使得互联网巨头构筑起了一个强势的供应商。消费者在它的面前，议价能力将大大降低。

这时，菜市场的优势就体现出来了。根本上讲，菜市场比平台更依赖社区、回头客等构成的熟人社会。在一个熟人社会中，消费者能够更从容地和菜市场商贩“讨价还价”，商贩也能准确了解消费者的意愿并作出调整。这能构建起互联网无法带来的良性互动。

菜市场对城市来说，意味着什么？

法国历史学家费尔南·布罗代尔曾经说过：没有市场就没有城市。可见，在人类的发展进程中，市场起到了十分关键的作用。

放到今天，我们已经不能再用单一的眼光来看菜市场这一公共区域了。我们到菜市场，也不再是满足购买需求这么简单了。

和家人遛弯买菜、与熟悉的商贩聊天和讨价还价、菜场和小摊的人情味和烟火气、通过商贩累积起的多年的邻里情……对于这个笼罩着“技术至上”氛围的社会来说，即便是一二线城市，也有大批菜市场的簇拥者独立于互联网的浪潮之外。

菜市场不仅是社交场景的重要承载地，也是保障民生的重要存在。对于消费者来说，它只是我们购物的一个选择，但对菜市场的一些商贩来说，这是他们赖以生存的“港湾”。

近几年，不少地区的政府也都已经在出台相关规定，为菜市场改造升级提供补助。2017年起，北京发改委计划连续3年每年出资两亿元，补助商业便民服务设施建设，其中菜市场是补助的重点。这两年，广州也在实施菜市场升级改造工程。上海十多年前就开始整顿马路菜场，随着旧城改造工程的推进，新建了大批室内菜市场。

诚然，互联网嵌入日常生活的大趋势是不可阻挡的。如何让互联网更好便利我们生活的同时，让菜市场在这场大潮中适应并升级？如何让互联网电商与小商小贩在合理的市场规则下共生？这是我们需要思考的问题。

50位演藝圈名人感動力薦《親愛的殺手》
邱偲栞映後座談角色上身數度泛淚

金馬獎最佳改編劇本提名賴孟傑全新編導話題新作《親愛的殺手》，由「荷爾蒙男星」鄭人碩攜手「小金泰熙」邱偲栞挑戰從影最大尺度演出，並集結喜翔、黃采儀、鄭志偉等實力派金獎陣容，聯手打造今年度最具話題情慾國片，更獲選爲本屆高雄電影節開幕片與香港電影節新秀電影競賽單元，電影於上週五正式上映後，以獨特寫實的社會題材，深刻描寫出社會底層人物的情感，更是被資深影評人吳文智譽爲「台版綠洲」！電影上映後，導演賴孟傑與主演鄭人碩、邱偲栞、喜翔在首週末三天，兵分二路勤跑各大戲院映後QA謝票，邱偲栞每每分享都泛淚直說：「再次想起片中角色的心境讓我很難過，很開心能藉由這部電影讓觀眾看到不一樣的我。」除此之外，超過50位演藝圈名人好友們也都大方力挺支持，徐若瑄大讚：「大膽、勇敢、寫實！」；林依晨看完電影後則有感而發表示：「照顧者與被照顧者都是被困住的人，什麼是真正的自由？什麼才是無盡的牢籠？」

電影《親愛的殺手》上週五在台上映，劇情深刻地描寫社會底層人物的無助與無奈，導演賴孟傑不僅寫實地呈現出社會上某個角落的縮影，更將片中鄭人碩、邱偲栞的情慾戲拍得唯美浪漫，兩人刻苦銘心的愛情令人深感揪心，許多觀眾看完電影後好評讚賞：「儘管故事中有許多悲劇，但看完電影後得到的卻是一絲希望。」、「導演沒有刻意販賣愛情，反而給了他們在無人看見的角落留有希望！」此外，上週末三天，主創團隊在台北兵分兩路，勤跑映後座談活動，觀眾們皆熱情踴躍提問，也讓邱偲栞坦言彷彿片中角色「泡麵」再度上身，數度感動泛淚：「再度回憶起泡麵的心境讓我忍不住想哭，真的很喜歡這個劇本，也非常開心，透過這部電影可以讓更多人看見不一樣的我！」鄭人碩則是分享：「電影中的角色雖然看似跟過往的演出一樣悲慘，但希望大家都能看出我不一樣的演出方式。」

不只網路上引發話題，演藝圈名人看完電影後也紛紛推薦力挺支持，其中「小徐監製」徐若瑄大讚：「大膽、勇敢、寫實，是一部特別的電影！」；邵雨薇則表示：「看到互相依靠的兩個人，浪漫與痛苦扭曲交織在一起。」；林依晨看完電影後有感而發在IG上發文分享：「兩個孤獨而不敢期待被愛、不能盼望未來的靈魂，反而能夠擁抱彼此殘缺。長照議題裡，照顧者與被照顧者都是被困住的人，什麼是真正的自由？什麼才是無盡的牢籠？」另外還有蔡淑臻、李淳、李杏、李沐、魏曼、蘇達、蔡瑞雪、陸明君、曾少宗、鄒承恩、姚亦晴、辛樂兒、劉奕兒、蔡凡熙、蔡黃汝、曾珮瑜、唐振剛、項婕如、梁以辰、梁赫群、馬國賢、涂善存、蔡允潔、杜妍、管麟、應蔚民、資深影評人吳文智、資深影評人麥若愚…等，超過50位演藝圈好友們皆給予好評，並力薦觀眾一定要進戲院支持！

六（鄭人碩 飾）是位靠販售愛心商品維生的身障人士，生活大小事都需倚賴父親（喜翔 飾）幫忙，從未談過戀愛的他，對於性有著無限的憧憬與幻想，在大樓保全文哥（鄭志偉 飾）的引介下，六認識了一個沉默的少女泡麵（邱偲栞 飾），長年生活在陰暗狹小文具店的她，不僅要照顧有心理疾病的母親（黃采儀 飾），在學校也備受同儕霸凌。對未來不抱期待的泡麵，與六從平淡的性交易關係，逐漸發展出一段刻骨銘心的愛情，同時六也發現文哥與泡麵似乎也有著不尋常的關係… 同樣生活在灰色角落的他們，透過相遇的微光溫熱了彼此的心，因慾望點燃了希望，兩人最終能否走出生命的困境…？《親愛的殺手》將於2020年12月4日全台上映。

大霈《囍宴機器人》相親結婚
透露現實生活也有被安排相親

由綺影映畫主辦、高雄市電影館協辦，Janet（謝怡芬）、George（吳宇衛）夫妻檔及李霈瑜（大霈）合演的台法合製VR電影《囍宴機器人》，即將推出2020沉浸式體驗版本，並於北、高兩地巡迴演出。今(12/10)於「濕地｜venue」舉辦記者會，而在片中飾演新郎的George因故無法到場，所以由飾演新娘的大霈偕同扮演機器人的Janet一同出席，兩人平時就是感情很好的師姊師妹檔，這次在片中飾演新娘和伴娘之間的關係，而現實生活中，新郎George與機器人Janet與目前已經懷了第二胎，即將於2月迎接寶寶的誕生。記者會上，Janet看起來氣色非常好，活力十足，對於2018年演出的VR作品要正式上映感到非常興奮，「這是一個全新的上映計畫，不是像一般我們想看電影到戲院去看電影，我們很用心打造整個場地，讓大家在進來這個空間的那刻起觀眾也參與在戲劇演出裡。」而談到沉浸式體驗，Janet也提到在參加日舞影展時，扮演和片中一樣的機器人驚喜出現在展場裡，「看觀眾在看影片的反應非常有趣，我特別挑了反應很大的觀眾在影片結束後摘掉眼鏡，嚇得他們滿口髒話，非常可愛！」而大霈當時因爲工作關係沒有機會到美國參與日舞影展，所以知道臺灣也要上映沉浸式體驗非常興奮，「雖然已經知道故事在講什麼，但和不同的人體驗這個全新的沉浸式腳本，相信一定會超好玩的！」

而在片中，大霈飾演的宋珍珍被安排與George相親結婚，大霈也透露現實生活中也有被爸爸安排想要和朋友的兒子相親，沒想到大霈對爸爸大發火，無法接受沒有感情基礎下和對方交往，監製笑著說：「和片中演出角色一模一樣欸！怪不得演得特別好！」而這次難得的師姐妹同台演戲，大霈還在Janet面前和George調情摸手，大霈笑著說這樣的經驗特別好玩！被問說之後還會不會想要一起合作演戲，是什麼樣的類型？會想要挑戰什麼角色，沒想到大霈語出驚人地說，什麼都想欸！謀殺劇情或綠茶婊！

而《囍宴機器人》監製陳斯婷（Estela）透露當初看到這個案子的腳本非常興奮，融合中西元素又多線式的敘述，認爲有非常多有趣的媒材可以發展這個故事，便積極爭取製作機會，而他們當下覺得發展VR是非常適合且有趣，於是先進行了VR拍攝的製作，也受到高雄市電影館的支持投資，讓這個作品完美誕生，獲得國際上各大影展的支持，又在文化部的補助之下發展了數位漫畫，而今日在記者會上，監製陳斯婷也正式宣布《囍宴機器人》要上市的年代，並經歷一場四十分進行影集開發，讓「囍宴」宇宙再更完整，而現場Janet及大霈聽完也興奮表示自己一定要參與演出，主持人開玩笑說兩位主演會不會很忙沒時間啊？大霈馬上自嘲說自己是金馬落馬女主角，很閒的啦！也期待並祝福影集順利開拍！

《囍宴機器人》爲綺影映畫與法國團隊Digital Rise共同推出之沉浸式體驗作品，以VR放映爲主軸結合互動演出及觀眾協助的沉浸式體驗。在這裡觀眾將成爲玩家，進入一個人型機器人已經鐘的沉浸式體驗。Mechlife爲一家致力於打造人型機器人的業界領導者，一間科技巨頭公司。觀眾在這場沉浸式體驗中，將被視爲Mechlife的新進員工。在Mechlife創新部門主管Angela及機器人Fred的帶領下，展開第一天員工訓練。訓練過程中，Angela將請所有新進員工觀看一段兩大家族聯姻的VR影片，找出片中意外事件的蛛絲馬跡，作爲公司在機器人研發的重要參考資料。VR影片中宋太太（郎祖筠飾演）爲了寶貝女兒珍珍（李霈瑜-大霈飾演）與新郎（George-吳宇衛飾演）的婚禮，挑選了最新一代測試機器人「阿慧」（Janet-謝怡芬飾演)作爲伴娘，一場意外事件卻掀起了聯姻背後的真相;在這裡唯有所有人的同心協力，才能看見影片中事件的原貌…。本作品獲文化部108年原創漫畫內容開發與跨業發展及行銷補助，12月11日起至20日止將在「濕地｜venue」（台北市中山區林森北路107巷10號3樓）作展演，12月24日起至2021年1月3日止將移師至高雄VR體感劇院（高雄市鹽埕區大義街駁二大義區C9倉庫）巡迴演出，票券現正於UDN售票網（https://pse.is/396wlw）熱賣中，贈送「一同咖啡聯名濾掛式咖啡包組」的早鳥套票目前已經完售，可購買指定場次會贈送「OOH LA LOVE」贊助之法式囍糖、「F2 Patisserie」贊助之精選法式小點，包場觀影還可獲得「青手作皂」贊助之「胺基酸晶亮皂+洗手皂」婚禮小物組（市值239）。

張艾嘉&李少紅&陳沖執導"世間有她"

易烊千璽周迅主演 重新定義女性電影



今日，由張艾嘉、李少紅、陳沖三位頂尖華語女性導演執導，著名女性電影人董文潔擔任總出品人的電影《世間有她》進行了全陣容官宣，並發布了主創全陣容海報，宣布影片將於2021年公映。影片陣容可謂豪華——周迅、易烊千璽、鄭秀文領銜主演，許娣、馮德倫、白客、黃米依、鮑起靜主演，朱雅芬、巴圖特別出演。明星戲骨加金牌女性導演組成的豪華陣容引人期待。

豪華陣容引爆期待

作爲壹部全部由女性電影人創作完成的高話題度電影，《世間有她》將視線聚焦在2020年。影片匯聚了三位最具實力的華語女導演。其中，演、導雙優的張艾嘉導演執導的電影《最愛》、《心動》等曾獲香港電影金像獎等多個獎項；身爲中國電影導演協會會長的李少紅導演執導的《紅粉》、《媽閣是座城》等作品是不可多得的佳作，少紅導演也因影片《紅粉》榮獲柏林電影節傑出個人成就銀熊獎；

而作爲奧斯卡終身評委、好萊塢編劇家協會會員的陳沖導演不僅多次擔任各大國際電影節評委，她執導的電影《天浴》等也曾獲臺灣電影金馬獎最佳影片、最佳導演等多項殊榮。三位優秀女性導演首次合作，無疑是影片最可靠的質量保證。據悉，早前官宣的俞飛鴻導演由於檔期原因不再執導《世間有她》，出品方向飛鴻導演的支持和付出表達由衷的敬意和感謝。

演員陣容上，電影《世間有她》由首位華語電影三大獎滿貫影後周迅、金像和百花獎最佳新人獎得主優秀青年演員易烊千璽、亞洲天後實力派偶像明星演員鄭秀文在三個故事中分別領銜主演，他們與主演許娣、馮德倫、白客、黃米依、鮑起靜默契搭檔合作，將特殊時期下被壓力裹挾、身處困境的普通人演繹得真切、出彩。

此外，影片還邀請到了91歲的著名鋼琴演奏家、教育家、鋼琴大師郎朗的恩師朱雅芬老師和“星二代”巴圖特別出演，爲本片共同奉獻了精彩絕倫的表演。

影片不僅匯聚演技與人氣兼具的魅力演員和橫跨老、中、青三代的優秀演員聯袂探討“愛與生命”等高熱議度主題，連許久未以演員身份出現的男神馮德倫也願意爲“她”挺身而出，陣容之豪華在華語女性電影史上可謂前所未有。

壹部影片全部由女性電影人操盤，並同時聚集三位頂級女性導演和如此之多的實力派與人氣演員，電影《世間有她》官宣伊始就引發了業內外的關註。影片全新的創作模式、嶄新的創作理念，不僅重新定義了女性電影，更有望打破華語女性電影的天花板，重新定義女性電影的市場維度。

主創親書金句“給她力量”

《世間有她》主創全陣容海報也於今日發布。11張海報保持統壹的設計風格，整體色調呈現出獨特的光影質感，大氣的構圖上壹抹亮色金句奪人眼目——每壹張海報上的暖心話語，分別由主創本人親手寫就：“心存信念，抵擋萬千”，“生活沒有答案，也不需要答案”，“妳比妳想象中更堅強”……

每位主創的臉上滿滿都是故事，表情、眼神充滿情感張力，每位主創身後，窗外居民樓的萬家燈火如同點點星光，飽含人世間的煙火氣和家的溫暖感，在爲觀眾帶來溫情和力量的同時，也透露出影片的視聽焦點就在這千家萬戶普通人的生活和情感。《世間有她》全陣容海報爲2020年末送上了壹抹冬日暖陽，影片的立意與力量，躍然而出。

聚焦2020 引發思考與共鳴

《世間有她》的故事背景設定在2020年：壹場突如其來的災難，打亂了所有人的生活。當工作面臨失業，當家庭分崩離析，當愛人分隔兩地，當死亡悄然逼近，當平靜的生活突然遭遇毫無征兆的變故，這時候的女性會怎樣應對？男性在女性的生命和成長中又擔當起怎樣至關重要無法替代的作用？

張艾嘉、李少紅、陳沖三位導演用各自獨特的女性視角，探索並展現了特殊時期人們在家庭、事業、愛情中的困境與掙紮，用最細膩的視聽語言帶給觀眾深層次的思考與啓發。影片將鏡頭對準充滿煙火氣的平凡生活，通過幾對人物的情感和故事映射出社會中萬千普通人在2020年的生存現狀，值得全社會體悟與思考，也必將引起觀眾的共鳴與共情。

電影《世間有她》由亞太未來影視（青島）有限公司、北京聚合影聯文化傳媒有限公司、時尚芭莎等頭部公司聯合出品，計劃於2021年與觀眾見面。

杜江王千源《驚天救援》首曝片場照

聚焦災後救援，記錄消防員救援的驚險過程

日，由彭順執導，杜江、王千源、佟麗婭、韓雪、俞灝明、韓東君、王戈領銜主演的電影《驚天救援》發布壹組工作照，災後救援場景首度曝光。影片講述壹場小地震引發多重災情，面對“全災種、大應急”的任務需求，救援隊員挺身而出赴湯蹈火的故事。目前，《驚天救援》正在緊鑼密鼓的拍攝當中。

本次曝光的片場照記錄了極具紀實感的災後廢墟場面。其中壹張現場救援圖格外引人註目，數名消防隊員奮不顧身展開速降救援，坍塌的斷面之下危機四伏，救援人員遭遇了哪些無法預知的危險？導演彭順介紹道：日前正在進行第壹場重場戲的拍攝，爲了還原最真實的救援行動，拍攝團隊在片場挖掘了壹個深度達10米，寬度50米的巨型深坑，不僅如此，劇組還陸續搭建了盤山公路隧道、核心爆炸區等多處重要場景，得到了應急管理部消防救援局、江蘇省消防救援總隊等等相關部門的專業指導和大力支持。

電影《驚天救援》由彭順導演，杜江、王千源、佟麗婭、韓雪、俞灝明、韓東君、王戈領銜主演，印小天、羅嘉良、蘇巖、伊麗媛、張逸倫、張竣傑等主演，將於2021年上映。



華府書友會/聖地牙哥作家協會「美麗心世界」系列講座（四）
劉嫄博士主講「東非古國Ethiopia衣索匹亞文化巡禮」（下）



介紹Kara族的人口、佔地及生活細節。

Kara族男子成年禮— 跳牛儀式。

醫療系統的新與舊。

Kara族人民迎著朝陽牧羊。

二級保護動物： 獅尾狒Gelada Baboon，僅伊索匹亞有。

Kara族特殊的面部及全身彩繪。

本報記者秦鴻鈞攝影

伊索匹亞深度行地圖 。

Kara族特殊的面部及全身彩繪。

當地交通的新與舊。

當地市場內新與舊，三種面貌成鮮明對比。